PTEN and prostate carcinoma: Importantly, co-treating a model of β-catenin activated and Pten-deficient prostate cancer with ADT (surgical castration) and the porcupine inhibitor LGK974 that blocks the secretion of Wnt ligands reduced tumor burden and proliferation in vivo, indicating combining AR and Wnt pathway targeted therapies are efficacious against Wnt-driven prostate cancer [18].